AVROBIO (Nasdaq:AVRO) - 주가, 뉴스 및 분석

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

AVRO 주식 개요

임상 단계의 유전자 치료 기업인 에이브로바이오는 미국에서 희귀 질환 치료를 위한 조혈 줄기세포 유전자 치료제를 개발하는 회사입니다.

AVRO 기본 분석
눈송이 점수
가치 평가	1/6
미래 성장	0/6
과거 실적	3/6
재무 상태	6/6
배당금	0/6

보상

가격 대비 수익 비율( 24.9 x)은 Biotechs 업계 평균( 27.2 x)보다 낮습니다.

올해부터 흑자전환

위험 분석

수익이 1백만 달러 미만인 경우 ( $0 )

수익은 향후 3년간 연평균 18.4% 씩 감소할 것으로 예상됩니다.

재무 결과에 영향을 미치는 대규모 일회성 항목

의미 있는 시가총액이 없습니다. ( $64M )

AVROBIO, Inc. 경쟁사

Spero Therapeutics

NasdaqGS:SPRO

US$70.2m

Eagle Pharmaceuticals

NasdaqGM:EGRX

US$72.7m

Protalix BioTherapeutics

NYSEAM:PLX

US$85.8m

CytomX Therapeutics

NasdaqGS:CTMX

US$95.1m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 AVROBIO
과거 주가
현재 주가	US$16.80
52주 최고치	US$19.80
52주 최저치	US$10.56
베타	1.22
11개월 변경	1.45%
3개월 변경 사항	9.38%
1년 변경 사항	44.82%
33년 변화	-85.45%
5년 변화	-90.89%
IPO 이후 변화	-95.51%

최근 뉴스 및 업데이트

Recent updates

Avrobio rises as gene therapy for Gaucher disease gets ILAP designation in UK

Oct 18

Avrobio stock rises as kidney disease gene therapy gets FDA rare pediatric disease status

Sep 20

Here's Why We're Not Too Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

Mar 08

AVROBIO: Undercovered Gene Therapy Developer With Excellent Promise

Dec 25

We Think AVROBIO (NASDAQ:AVRO) Can Afford To Drive Business Growth

Nov 23

AVROBIO readies $75M equity offering

Nov 19

AVROBIO EPS misses by $0.19

Nov 05

주주 수익률

	AVRO	US Biotechs	US 마켓
7D	-4.8%	-0.7%	0.07%
1Y	44.8%	10.2%	20.7%

수익률 대 산업: AVRO 지난 1년 동안 6.7 %를 반환한 US Biotechs 산업을 초과했습니다.

수익률 대 시장: AVRO 지난 1년 동안 23.3 %를 반환한 US 시장을 초과했습니다.

가격 변동성

Is AVRO's price volatile compared to industry and market?
AVRO volatility
AVRO Average Weekly Movement	5.6%
Biotechs Industry Average Movement	10.4%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.3%
10% least volatile stocks in US Market	2.8%

안정적인 주가: AVRO 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: AVRO 의 주간 변동성( 6% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
2015	13	Erik Ostrowski	www.avrobio.com

임상 단계의 유전자 치료 회사인 AVROBIO는 미국에서 희귀 질환 치료를 위한 조혈 줄기세포 유전자 치료제를 개발하는 회사입니다. 이 회사의 유전자 치료법은 환자로부터 채취한 조혈 줄기세포를 렌티바이러스 벡터로 변형하여 목표 질환에 돌연변이가 있는 유전자의 기능적 사본과 동일한 것을 삽입하는 방식을 사용합니다. 이 회사의 파이프라인에는 고셔병 1형과 3형 치료를 위한 임상 1/2상 시험 중인 AVR-RD-02, 파브리병 치료를 위한 임상 2상 시험 중인 AVR-RD-01, 폼페병 치료를 위한 전임상 단계인 AVR-RD-03 등이 있습니다.

AVROBIO, Inc. 기본 사항 요약

AVROBIO 의 수익과 매출은 시가총액과 어떻게 비교하나요?
AVRO 기본 통계
시가총액	US$63.75m
수익(TTM)	US$30.31m
수익(TTM)	n/a

24.9x

P/E 비율

0.0x

P/S 비율

AVRO 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
AVRO 손익 계산서(TTM)
수익	US$0
수익 비용	US$0
총 이익	US$0
기타 비용	-US$30.31m
수익	US$30.31m

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	0.68
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	0%

AVRO 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

This company is no longer active

AVRO 주식 개요

보상

위험 분석

AVROBIO, Inc. 경쟁사

NasdaqGS:SPRO

US$70.2m

NasdaqGM:EGRX

US$72.7m

NYSEAM:PLX

US$85.8m

NasdaqGS:CTMX

US$95.1m

가격 내역 및 성능

최근 뉴스 및 업데이트

Tectonic Therapeutic, Inc. completed the acquisition of AVROBIO, Inc. (NasdaqGS:AVRO) from a group of shareholders in a reverse merger transaction.

Investor sentiment improves as stock rises 1,043%

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

AVROBIO, Inc. (NasdaqGS:AVRO) entered into an agreement to acquire Tectonic Therapeutic, Inc.

Recent updates

Tectonic Therapeutic, Inc. completed the acquisition of AVROBIO, Inc. (NasdaqGS:AVRO) from a group of shareholders in a reverse merger transaction.

Investor sentiment improves as stock rises 1,043%

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

AVROBIO, Inc. (NasdaqGS:AVRO) entered into an agreement to acquire Tectonic Therapeutic, Inc.

AVROBIO, Inc. (NasdaqGS:AVRO) entered into an agreement to acquire Tectonic Therapeutic, Inc.

No longer forecast to breakeven

Price target decreased by 16% to US$3.00

New major risk - Revenue and earnings growth

Chief Business Officer notifies of intention to sell stock

Novartis Pharma AG and Novartis Pharmaceuticals Corporation entered into an Asset Purchase Agreement to acquire Cystinosis Gene Therapy Program from AVROBIO, Inc. (NasdaqGS:AVRO) for $87.5 million.

Price target decreased by 8.5% to US$3.58

Novartis Pharma AG and Novartis Pharmaceuticals Corporation entered into an Asset Purchase Agreement to acquire Cystinosis Gene Therapy Program from AVROBIO, Inc. (NasdaqGS:AVRO) for $87.5 million.

Co- Founder exercised options to buy US$104k worth of stock.

AVROBIO, Inc. Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for Its Gaucher Disease Gene Therapy

Price target decreased to US$4.14

Insufficient new directors

Avrobio Receives Rare Pediatric Disease Designation from the U.S. FDA for First-In-Class Gene Therapy for Gaucher Disease

AVROBIO, Inc. Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis

AVROBIO, Inc. announces U.K. Medicines and Healthcare products Regulatory Agency grant an Innovation Passport under the Innovative Licensing and Access Pathway

Avrobio rises as gene therapy for Gaucher disease gets ILAP designation in UK

AVROBIO, Inc. Reports Favorable Data on Use of Combined State-Of-The-Art in Vitro Cell-Based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development

AVROBIO Receives Written Notice from The Nasdaq Stock Market Regarding Minimum Bid Price Requirement

AVROBIO, Inc. Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for First Gene Therapy in Development for Cystinosis

Avrobio stock rises as kidney disease gene therapy gets FDA rare pediatric disease status

AVROBIO Inc. Announces Neuronopathic Mucopolysaccharidosis Type II or Hunter Syndrome Clinical Trial Application Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial

AVROBIO granted FDA’s orphan drug designation for metabolic disorder therapy

AVROBIO, Inc.(NasdaqGS:AVRO) dropped from Russell 2500 Index

AVROBIO, Inc. Announces Preclinical Data Demonstrating the Efficacy and Safety of AVR-RD-03 Gene Therapy in A Mouse Model of Infantile Onset Pompe Disease

Avrobio Reports Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures

Price target decreased to US$6.29

Insufficient new directors

AVROBIO, Inc. Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis

Insufficient new directors

Insufficient new directors

AVROBIO, Inc. Announces the Appointment of Sean O’Bryan as Chief Regulatory Officer

AVROBIO, Inc. Announces New Data from Phase 2 Fab-Gt Clinical Trial Show Variable Engraftment

AVROBIO, Inc Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safety Data for Investigational Gene Therapies in Fabry Disease and Gaucher Disease Type 1

Price target decreased to US$22.88

Price target increased to US$25.14

Here's Why We're Watching AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

We're Keeping An Eye On AVROBIO's (NASDAQ:AVRO) Cash Burn Rate

AVROBIO, Inc.(NasdaqGS:AVRO) dropped from Russell 2500 Growth Index

AVROBIO: Fabrazyme's Full Approval Changes Things

AVROBIO, Inc. Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease

AVROBIO, Inc. Announces Two Oral Presentations and Two Posters Featuring Data from Its Pipeline of Lysosomal Disorder Gene Therapy

Here's Why We're Not Too Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

Price target lowered to US$34.50

AVROBIO, Inc. Receives Orphan Drug Designation from the European Commission for AVR-RD-04, an Investigational Gene Therapy for Cystinosis

AVROBIO, Inc. Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in First Patient Dosed with plato Gene Therapy Platform in Fabry Disease Phase 2 Trial

New 90-day high: US$17.11

Avrobio Appoints Diana M. Escolar as Chief Medical Officer

AVROBIO, Inc. Appoints Diana M. Escolar as Chief Medical Officer

AVROBIO: Undercovered Gene Therapy Developer With Excellent Promise

We Think AVROBIO (NASDAQ:AVRO) Can Afford To Drive Business Growth

AVROBIO readies $75M equity offering

AVROBIO, Inc. Avrobio Announces New Positive Clinical Data and Preclinical Data, as Well as Expanded Leading Lysosomal Disorder Gene Therapy Pipeline